Gebelikte COVID-19 hastalığının takip ve tedavisi

Tüm Dünya’da hızla yayılmaya devam eden, üzerinde birçok çalışma ve araştırmanın devam ettiği, birçok bilinmeyeni olan COVID-19’un gebelerdeki seyri de tartışmalıdır. Enfekte gebelerin çoğu (>%90) hastaneye yatmadan iyileşse de, hızlı klinik bozulma meydana gelebilir ve semptomatik gebe hastalar, üreme çağındaki semptomatik gebe olmayan kadınlara kıyasla ciddi hastalık ve ölüm riski altında görünmektedir. Gebelikte ciddi hastalık ve ölüm için risk faktörleri arasında ileri yaş (özellikle ≥35 yaş), obezite ve komorbiditeler (özellikle hipertansiyon ve diyabet veya birden fazla komorbidite) yer alır. Bu derlemenin amacı gebelerde COVID-19’un epidemiyolojisi, bulaş yolları, kliniği, komplikasyonları, tanısı, tedavisi, korunma önlemleri ve takibini özetlemektir.

Anahtar Kelimeler:

COVID-19, gebelik, sars-coV 2

Follow-up and treatment of COVID-19 disease in pregnancy

The course of COVID-19 in pregnant women, which continues to spread rapidly all over the world, on which many studies and researches continue, and which has many unknowns, is also controversial. Although most (>90%) infected pregnant women recover without hospitalization, rapid clinical deterioration can occur and symptomatic pregnant patients appear to be at greater risk of serious illness and death compared to symptomatic nonpregnant women of reproductive age. Risk factors for serious illness and death in pregnancy include older age (especially ≥35 years), obesity and comorbidities (especially hypertension and diabetes or multiple comorbidities). The aim of this review is to summarize the epidemiology, transmission routes, clinic, complications, diagnosis, treatment, prevention measures and follow-up of COVID-19 in pregnant women.

Keywords:

COVID-19, pregnancy, SARS-CoV-2,

PDF

___

1. Breslin N, Baptiste C, Gyamfi-Bannerman C, et al. COVID-19 infection among asymptomatic and symptomatic pregnant women: Two weeks of confirmed presentations to an affiliated pair of New York City hospitals. Am J Obstet Gynecol MFM 100118 . 2020; https://doi.org/10.1016/j.ajogmf.2020.100118, 2. Sutton D, Fuchs K, D’Alton M, et al. Universal Screening for SARS-CoV-2 in Women Admitted for Delivery. N Engl J Med 382:2163–4. 2020; . https://doi.org/10.1056/NEJMc2009316
3. Di Mascio D, Khalil A, Saccone G, et al. Outcome of Coronavirus spectrum infections (SARS, MERS, COVID 1 -19) during pregnancy: a systematic review and meta-analysis. Am J Obstet Gynecol MFM 100107. 2020; . https://doi.org/10.1016/j.ajogmf.2020.100107
4. Schwartz DA An Analysis of 38 Pregnant Women with COVID-19, Their Newborn Infants, and Maternal-Fetal Transmission of SARS-CoV-2: Maternal Coronavirus Infections and Pregnancy Outcomes. Arch Pathol Lab Med. 2020; https://doi.org/10.5858/arpa.2020-0901-SA
5. Khan S, Jun L, Nawsherwan null, et al. Association of COVID-19 with pregnancy outcomes in health-care workers and general women. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis 26:788–90 . 2020; https://doi.org/10.1016/j.cmi.2020.03.034
6. Yang H, Sun G, Tang F, et al. Clinical features and outcome